Filtered By:
Condition: Diabetes
Countries: Japan Health

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 325 results found since Jan 2013.

Different Determinants of the Recurrence of Atrial Fibrillation and Adverse Clinical Events in the Mid-Term Period After Atrial Fibrillation Ablation
CONCLUSIONS: This study disclosed different determinants of post-ablation recurrence and AEs. Female sex, persistent AF, and enlarged LAd were determinants of post-ablation recurrence, whereas an old age, comorbidities, and LV and renal dysfunction rather than post-ablation recurrence were AEs determinants. These findings will help determine ablation indications and post-ablation management.PMID:34219078 | DOI:10.1253/circj.CJ-21-0326
Source: Circulation Journal - July 5, 2021 Category: Cardiology Authors: Ryuta Watanabe Koichi Nagashima Yuji Wakamatsu Naoto Otsuka Katsuaki Yokoyama Naoya Matsumoto Takayuki Otsuka Shinya Suzuki Akio Hirata Masato Murakami Mitsuru Takami Masaomi Kimura Hidehira Fukaya Shiro Nakahara Takeshi Kato Hiroshi Hayashi Yu-Ki Iwasaki Source Type: research

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

The Modified Chronic Kidney Disease Epidemiology Collaboration Equation for the Estimated Glomerular Filtration Rate is Better Associated with Comorbidities than Other Equations in Living Kidney Donors in Japan
Conclusion We found that the eGFR/Jm-CKD-EPI correlated better with comorbidities than the eGFR/Jm-eGFR and eGFR/Jm-MDRD in Japanese LKT donors. We recommend using the eGFR/Jm-CKD-EPI for the initial assessment of the renal function in LKT donor candidates when evaluating the presence of associated comorbidities.PMID:33716291 | DOI:10.2169/internalmedicine.6934-20
Source: Internal Medicine - March 15, 2021 Category: Internal Medicine Authors: Shinichi Nishi Shunske Goto Makiko Mieno Takashi Yagisawa Kenji Yuzawa Source Type: research

Incidence of adverse cardiovascular events in type  2 diabetes mellitus patients after initiation of glucose‐lowering agents: A population‐based community study from the Shizuoka Kokuho database
ConclusionsThe incidence of HHF was similar to that of stroke. A significant portion of our cohort met the inclusion criteria for major randomized clinical trials for SGLT2i, and estimated reduction in the HHF events was substantial.
Source: Journal of Diabetes Investigation - January 29, 2021 Category: Endocrinology Authors: Shun Kohsaka, Hiraku Kumamaru, Shiori Nishimura, Satoshi Shoji, Eiji Nakatani, Nao Ichihara, Hiroyuki Yamamoto, Yoshiki Miyachi, Hiroaki Miyata Tags: Original Article Source Type: research

Consumption of flavonoid-rich fruits, flavonoids from fruits, and stroke risk: a prospective cohort study.
Abstract We sought to examine the prospective associations of specific fruit consumption, in particular flavonoid-rich fruit (FRF) consumption, with the risk of stroke and subtypes of stroke in a Japanese population. A study followed a total of 39,843 men and 47,334 women aged 44-76 years, and free of cardiovascular disease, diabetes, and cancer at baseline since 1995 and 1998 to the end of 2009 and 2012, respectively. Data on total and specific FRF consumption for each participant were obtained using a self-administrated food frequency questionnaire. The hazard ratios (HRs) of stroke in relation to total and spec...
Source: The British Journal of Nutrition - January 29, 2021 Category: Nutrition Authors: Gao Q, Dong JY, Cui R, Muraki I, Yamagishi K, Sawada N, Iso H, Tsugane S, Japan Public Health Center-based Prospective Study Group Tags: Br J Nutr Source Type: research